Status:
COMPLETED
Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients
Lead Sponsor:
AstraZeneca
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study is to assess the safety and tolerability of Cediranib (RECENTIN™, AZD2171)in combination with etoposide and cisplatin (EP) as first line treatment for lung cancer patients with extensive st...
Eligibility Criteria
Inclusion
- Cancer diagnosis and stage (histological or cytological confirmed extensive stage lung cancer, which EP would be considered a standard therapy, required at the time of diagnosis.)
- No prior chemotherapy or immunotherapy for advanced stage lung cancer (prior radiotherapy will be permitted if it is outside of the measurable field and greater than or equal to 2 weeks prior to entry to the study.)
- WHO performance status 0-2
Exclusion
- Untreated unstable brain or meningeal metastases
- Patient with inappropriate laboratory tests values
- Inadequate bone marrow reserve.
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT00621361
Start Date
February 1 2008
End Date
February 1 2012
Last Update
December 17 2012
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Sacramento, California, United States
2
Research Site
Denver, Colorado, United States
3
Research Site
Kansas City, Kansas, United States
4
Research Site
Houston, Texas, United States